Search Result

Results for "

combined therapy

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Linker (1) Akt (1) Apoptosis (2) Autophagy (1) Bacterial (1) Carbonic Anhydrase (1) DNA/RNA Synthesis (1) FAK (1) Fluorescent Dye (1) GSK-3 (2) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) MAP4K (2) Microtubule/Tubulin (2) P-glycoprotein (1) Phosphodiesterase (PDE) (2) PROTAC Linkers (2) PROTACs (1) Radionuclide-Drug Conjugates (RDCs) (3) Reactive Oxygen Species (ROS) (1)
By Research Areas:	Cancer (15) Neurological Disease (2)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W035709

Hydrocinchonine Dihydrocinchonine	P-glycoprotein Apoptosis	Cancer
Hydrocinchonine (Dihydrocinchonine) is a multidrug resistance (MDR)-reversal agent. Hydrocinchonine directly inhibits the function and expression of P-gp, which is the mechanism by which it reverses MDR. Hydrocinchonine exerts synergistic apoptotic effect with Paclitaxel (HY-B0015) in MES-SA/DX5 cells. Hydrocinchonine can be used for the study of gynecological malignant tumors (such as uterine sarcoma) with drug resistance caused by excessive expression of P-gp .

HY-W040270

Amino-PEG10-amine	PROTAC Linkers	Cancer
Amino-PEG10-amine, a PEG-based PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer .

HY-130411

Amino-PEG11-amine	PROTAC Linkers	Cancer
Amino-PEG11-amine, a PEG-based (12 units) PROTAC linker used to combine two mono diethylstilbestrol (DES)-based ligands, provides an alternative strategy for preparing more selective and active ER antagonists for endocrine therapy of breast cancer .

HY-132989

Mal-Deferoxamine	Reactive Oxygen Species (ROS) Apoptosis Autophagy HIF/HIF Prolyl-Hydroxylase Akt Radionuclide-Drug Conjugates (RDCs)	Cancer
Mal-Deferoxamine is a maleamide (Mal)-containing Deferoxamine (HY-B1625). Mal selectively covalently binds to sulfur groups to produce a linking reaction. Mal-Deferoxamine can be combined with radionuclides to synthesize radionuclide drug conjugates (RDCs). RDCs have the ability to specifically target biomolecules and can be used in medical imaging or therapy. .

HY-117980

Meturedepa AB 132	DNA/RNA Synthesis	Cancer
Meturedepa (AB 132) functions as a radiation sensitizer, enhancing the biological effects of radiation. When combined with suboptimal doses of X-ray radiation, this combined therapy achieves better outcomes in terms of tumor shrinkage compared to Meturedepa used alone. Meturedepa is applicable in the research of bronchogenic carcinoma .

HY-169187

Antibacterial agent 247	Bacterial	Cancer
Antibacterial agent 247 (compund 30b) is a bacterial antagonist that significantly inhibits the formation of Pseudomonas aeruginosa biofilm (IC₅₀=5.8 μM) and multiple virulence phenotypes, and enhances its interaction with Tob Antibacterial activity of combined therapy with ampicillin and polymyxin B .

HY-159770A

(S)-EB-FAPI-B2	Radionuclide-Drug Conjugates (RDCs)	Cancer
(S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging or therapy .

HY-157529

IR820-PTX	Microtubule/Tubulin Fluorescent Dye	Cancer
IR820-PTX, an IR-820 (HY-136886)-Paclitaxel (HY-B0015) conjugate, is an amphipathic small molecule prodrug. IR820-PTX effectively inhibits tumor growth via combined photothermal therapy (PTT) and chemotherapy .

HY-106072

Vinzolidine LY 104208	Microtubule/Tubulin	Cancer
Vinzolidine is a semisynthetic derivative of the catharanthus alkaloid. Vinzolidine exerts its cytotoxic effect on tumor cells by interfering with microtubulin polymerization, thereby inhibiting cell division. Vinzolidine can be utilized in research to investigate synergistic effects when combined with other chemotherapeutic agents or biologic therapies, as well as to study cancer cells' tolerance or resistance to these treatments, and to explore approaches to overcome such obstacles .

HY-128879

VP3.15	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) .

HY-128879A

VP3.15 dihydrobromide 3 Publications Verification	Phosphodiesterase (PDE) GSK-3	Neurological Disease
VP3.15 dihydrobromide is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC₅₀s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 dihydrobromide has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS) .

HY-178097

HPK1-IN-62	MAP4K	Cancer
HPK1-IN-62 is a selective and orally active HPK-1 inhibitor with an IC₅₀ of 1.22 nM. HPK1-IN-62 significantly improves GLK selectivity (> 665-fold) and LCK selectivity (> 1095-fold). HPK1-IN-62 enhances T-cell activation and demonstrated synergistic effects when combined with anti-mPD-1 therapy in the MC38 tumor model, inhibiting a tumor growth. HPK1-IN-62 can be used in the researchs of colon cancer and cancer immunotherapy .

HY-173116

DOTA-XYIMSR-01	Carbonic Anhydrase	Cancer
DOTA-XYIMSR-01 is a molecular probe targeting CAIX that can be labeled with 177Lu for the inhibition and localization of malignant gliomas. The uptake of [177Lu] Lu-XYIMSR-01 in U87MG tumors is 6.19 % of the injected dose per gram (% ID/g), and the tumor-to-muscle uptake ratio is 20.14. In the orthotopic glioma model, combined injection with Temozolomide (HY-17364) can significantly improve the survival rate of mice and inhibit tumor growth. DOTA-XYIMSR-01 shows promise for research in the field of anti-cancer therapy .

HY-117947

(R)-OR-S1	Histone Methyltransferase	Cancer
(R)-OR-S1 is an isomer of OR-S1. The dual ZH1/2 inhibitors OR-S1 and OR-S2 exhibit strong inhibitory activity against both EZH1 and EZH2. OR-S1 and OR-S2 are highly selective methyltransferase inhibitors against EZH1 and EZH2, and they have very similar molecular features. Therefore, we investigated the effect of OR-S1 on acute myeloid leukemia (AML). We found that OR-S1 was able to induce cell differentiation and apoptosis in AML cells. These findings encouraged us to investigate whether functional LT-HSCs could survive PRC2-targeted therapy with OR-S1 or OR-S1 combined with cytarabine. The results showed that OR-S1 did not cause significant myelosuppression, and BM cells treated with the combination therapy were able to undergo normal hematopoiesis even 4 months after treatment. Therefore, temporary inhibition of EZH1 and EZH2 is clinically tolerable, making this combination therapy suitable for AML patients. AML is generally believed to originate from myeloid progenitor cells that inherit a large number of biological properties.

HY-100138

2-Aminoethyl-mono-amide-DOTA-tris(tBu ester)	Radionuclide-Drug Conjugates (RDCs) ADC Linker	Cancer
2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) is a metal chelator precursor containing a DOTA macrocyclic structure. DOTA can form highly stable complexes with metal ions (such as ⁶⁸Ga, ¹⁷⁷Lu) through four nitrogen atoms and four carboxylic acid groups to mediate targeted delivery of radionuclides. The tert-butyl ester group (tBu ester) of 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) also protects the carboxylic acid group during synthesis, and forms a free carboxyl group after deprotection reaction for coupling with targeting molecules (such as antibodies, peptides). 2-Aminoethyl-mono-amide-DOTA-tris(tBu ester) may be combined with tumor pre-targeting systems through bioorthogonal reactions (such as reverse electron demand Diels-Alder reaction) to study radioactive imaging or therapy of tumor tissues, and is mainly used in tumor pre-targeting research in the field of nuclear medicine .

HY-116497

PH11	FAK	Cancer
PH11 is a novel focal adhesion kinase (FAK) inhibitor that rapidly induces apoptosis in TRAIL-resistant PANC-1 cells when combined with TRAIL, but has no effect on normal human fibroblasts. The study found that PH11 downregulates c-FLIP through inhibition of FAK and phosphatidylinositol-3-kinase (PI3K)/AKT pathways, thereby restoring the TRAIL apoptotic pathway, suggesting that this combination therapy may provide an attractive therapeutic strategy for the safe and effective treatment of pancreatic cancer. PH11 selectively inhibits c-FLIP expression by modulating upstream signaling pathways and may represent an innovative therapeutic strategy. Although further work is needed to fully elucidate the mechanism of PH11-induced TRAIL sensitization, we believe that our results will provide a new approach to target c-FLIP without the risk of interfering with caspase-8 processing, which could potentially lead to TRAIL resistance. This study also suggests a role for the FAK/AKT signaling pathway in regulating c-FLIP expression in TRAIL-induced apoptosis, and this understanding will provide important clues to control the resistance mechanism to optimize the potential of TRAIL-based pancreatic cancer treatment.

HY-162816

PROTAC HPK1 Degrader-3	PROTACs MAP4K	Cancer
PROTAC HPK1 Degrader-3 (compound C3) is an orally effective PROTAC targeting HPK1 (DC₅₀=21.26 nM). HPK1 is a negative regulator of T cell receptors, which can lead to T cell dysfunction after abnormal activation. PROTAC HPK1 Degrader-3 can inhibit SLP76 and NF-κB signaling pathways and inhibit MAPK signal transduction, and has anticancer activity and immune activation. PROTAC HPK1 Degrader-3 has a certain oral bioavailability and can be combined with PD-L1 antibody therapy to achieve a tumor growth inhibition rate of 65.58%. PROTAC HPK1 Degrader-3 is composed of E3 ligase ligand Thalidomide (HY-14658; blue part), PROTAC linker tert-Butyl 3-oxoazetidine-1-carboxylate (HY-40146; black part), and target protein ligand HPK1-IN-51 (HY-162842; red part); the activity control of the target protein ligand can be HPK1 ligand 1 (HY-162841) ^{[1] ^.}

Cat. No.	Product Name

HY-L087

Anti-Obesity Compound Library	3,111 compounds
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,111 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Anti-Obesity Compound Library

3,111 compounds

Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries.

MCE Anti-Obesity Compound Library owns a unique collection of 3,111 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W035709

Hydrocinchonine Dihydrocinchonine	Alkaloids Other Alkaloids Source classification Rubiaceae Neolamarckia cadamba (Roxb.) Bosser Plants	P-glycoprotein Apoptosis
Hydrocinchonine (Dihydrocinchonine) is a multidrug resistance (MDR)-reversal agent. Hydrocinchonine directly inhibits the function and expression of P-gp, which is the mechanism by which it reverses MDR. Hydrocinchonine exerts synergistic apoptotic effect with Paclitaxel (HY-B0015) in MES-SA/DX5 cells. Hydrocinchonine can be used for the study of gynecological malignant tumors (such as uterine sarcoma) with drug resistance caused by excessive expression of P-gp .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks